Revisiting dezocine for opioid use disorder: A narrative review of its potential abuse liability

被引:1
作者
Barr, Gordon A. [1 ,2 ,3 ]
Schmidt, Heath D. [4 ,5 ]
Thakrar, Ashish P. [6 ,7 ]
Kranzler, Henry R. [5 ,8 ]
Liu, Renyu [2 ,9 ]
机构
[1] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Anesthesiol & Crit Care Med, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Nursing, Dept Biobehav Hlth Sci, Philadelphia, PA 19104 USA
[5] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA
[6] Univ Penn, Perelman Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA
[7] Univ Penn, Penn Ctr Addict Med & Policy, Perelman Sch Med, Philadelphia, PA 19104 USA
[8] Crescenz VAMC, Vet Integrated Serv Network 4, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA
[9] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA
关键词
biased mu-opioid ligand; dependence; dezocine; drug discrimination; drug self-administration; opioid use disorder; RESPIRATORY DEPRESSION; CELLS;
D O I
10.1111/cns.70034
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Aims: Opioid use disorder (OUD) remains a serious public health problem. Opioid maintenance treatment is effective but under-utilized, hard to access under existing federal regulations, and, once patients achieve OUD stability, challenging to discontinue. Fewer than 2% of persons with OUD stop using opioids completely. There have been calls from public advocacy groups, governmental agencies, and public health officials for new treatments for OUD. Dezocine, a non-scheduled opioid previously used in the United States and currently widely prescribed in China for pain management, could be a candidate for a novel OUD treatment medication in the U.S. Nonetheless, to date, there have been no reviews of the clinical and preclinical literature detailing dezocine's abuse potential, a key consideration in assessing its clinical utility. Discussion: There are no English language reports of human abuse, dependence, or overdose of dezocine, despite years of extensive clinical use. There are a few case reports of dezocine abuse in the Chinese literature, but there are no reports of overdose deaths. Dezocine is perceived as an opioid and is "liked" by opioid-experienced human and non-human primates, properties that are not dose-dependent and are mitigated by ceiling effects-higher doses do not result in more "liking." There is little withdrawal, spontaneous or precipitated, in humans, monkeys, rats, or mice treated chronically with dezocine alone. However, at some doses, dezocine can precipitate withdrawal in humans and monkeys dependent on other opioids. In rodents, dezocine reduces the severity of morphine withdrawal and the rewarding properties of other opioids. Conclusions: Although dezocine is reinforcing in humans and monkeys with prior or concurrent opioid use within a restricted dose range, there are only a few anecdotal reports of dezocine abuse despite of the long history of use in humans. Given the evidence of dezocine's limited abuse potential, it could be useful both as a treatment for OUD. However, in-depth studies would be required for dezocine to be re-considered for clinical use.
引用
收藏
页数:10
相关论文
共 65 条
  • [41] Shen Q., 2023, Chinese Pharmacovigilance, V20, P1181
  • [42] Effectiveness of nicotine gum in preventing lapses in the face of temptation to smoke among non-daily smokers: a secondary analysis
    Shiffman, Saul
    Ferguson, Stuart G.
    Mao, Jason
    Scholl, Sarah M.
    Hedeker, Donald
    Tindle, Hilary A.
    [J]. ADDICTION, 2020, 115 (11) : 2123 - 2129
  • [43] Dezocine promotes T lymphocyte activation and inhibits tumor metastasis after surgery in a mouse model
    Song, Qiang
    Liu, Geng
    Liu, Dongyi
    Feng, Chang
    [J]. INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1342 - 1349
  • [44] Steer CD., 2019, The Impact of Opiate Substitution Treatment on Mortality Risk in Drug Addicts: a Natural Experiment Study, V7, P1
  • [45] Opioid antagonist effects of dezocine in opioid-dependent humans
    Strain, EC
    Preston, KL
    Liebson, IA
    Bigelow, GE
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (02) : 206 - 217
  • [46] Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic
    Tanz, Lauren J.
    Jones, Christopher M.
    Davis, Nicole L.
    Compton, Wilson M.
    Baldwin, Grant T.
    Han, Beth
    Volkow, Nora D.
    [J]. JAMA NETWORK OPEN, 2023, 6 (01) : E2251856
  • [47] Trends in Before Medically Advised Discharges for Patients With Opioid Use Disorder, 2016-2020
    Thakrar, Ashish P.
    Lowenstein, Margaret
    Greysen, S. Ryan
    Delgado, M. Kit
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (23): : 2302 - 2304
  • [48] Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder
    Thakrar, Ashish P.
    Uritsky, Tanya J.
    Christopher, Cara
    Winston, Anna
    Ronning, Kaitlin
    Sigueza, Anna Lee
    Caputo, Anne
    McFadden, Rachel
    Olenik, Jennifer M.
    Perrone, Jeanmarie
    Delgado, M. Kit
    Lowenstein, Margaret
    Compton, Peggy
    [J]. ADDICTION SCIENCE & CLINICAL PRACTICE, 2023, 18 (01)
  • [49] Opioid withdrawal management in the fentanyl era
    Thakrar, Ashish P.
    Kleinman, Robert A.
    [J]. ADDICTION, 2022, 117 (09) : 2560 - 2561
  • [50] Multimodal drug addiction treatment: A field comparison of methadone and buprenorphine among heroin- and cocaine-dependent patients
    Vigezzi, Pierluigi
    Guglielmino, Livia
    Marzorati, Paolo
    Silenzio, Rosella
    De Chiara, Margherita
    Corrado, Filomena
    Cocchi, Laura
    Cozzolino, Edoardo
    [J]. JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2006, 31 (01) : 3 - 7